CA2232604C - Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament - Google Patents

Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament Download PDF

Info

Publication number
CA2232604C
CA2232604C CA002232604A CA2232604A CA2232604C CA 2232604 C CA2232604 C CA 2232604C CA 002232604 A CA002232604 A CA 002232604A CA 2232604 A CA2232604 A CA 2232604A CA 2232604 C CA2232604 C CA 2232604C
Authority
CA
Canada
Prior art keywords
aqueous solution
concentration
salt
solution
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002232604A
Other languages
English (en)
French (fr)
Other versions
CA2232604A1 (fr
Inventor
Claude Sene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of CA2232604A1 publication Critical patent/CA2232604A1/fr
Application granted granted Critical
Publication of CA2232604C publication Critical patent/CA2232604C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA002232604A 1996-07-16 1997-07-15 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament Expired - Lifetime CA2232604C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR96/08851 1996-07-16
FR9608851A FR2751343B1 (fr) 1996-07-16 1996-07-16 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
PCT/FR1997/001308 WO1998002522A1 (fr) 1996-07-16 1997-07-15 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament

Publications (2)

Publication Number Publication Date
CA2232604A1 CA2232604A1 (fr) 1998-01-22
CA2232604C true CA2232604C (fr) 2005-06-28

Family

ID=9494078

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002232604A Expired - Lifetime CA2232604C (fr) 1996-07-16 1997-07-15 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament

Country Status (11)

Country Link
US (2) US6451256B1 (Sortimente)
EP (1) EP0853660B1 (Sortimente)
JP (1) JP3681401B2 (Sortimente)
AT (1) ATE231549T1 (Sortimente)
AU (1) AU711409B2 (Sortimente)
CA (1) CA2232604C (Sortimente)
DE (1) DE69718612T2 (Sortimente)
DK (1) DK0853660T3 (Sortimente)
ES (1) ES2187798T3 (Sortimente)
FR (1) FR2751343B1 (Sortimente)
WO (1) WO1998002522A1 (Sortimente)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
CA2353417C (en) * 1998-12-03 2008-04-22 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
FR2791999B1 (fr) * 1999-04-09 2001-09-07 Aventis Pharma Sa Composition destinee a la conservation d'adenovirus recombinants infectieux
HK1045716A1 (zh) 1999-04-09 2002-12-06 阿文蒂斯药物股份有限公司 用於保存感染性重組腺病毒的組合物
EP1263461A4 (en) 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2001085928A1 (en) * 2000-05-10 2001-11-15 Mitsubishi Pharma Corporation Method of preparing virus vector
JP2005517394A (ja) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
EP1465664A1 (en) * 2002-01-18 2004-10-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
KR100507794B1 (ko) * 2003-02-11 2005-08-17 한미약품 주식회사 고농도 레트로 바이러스 현탁액 제조 방법
US20070148765A1 (en) * 2003-11-19 2007-06-28 Evans Robert K Preservative-containing virus formulations
DE602005015332D1 (de) * 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
GB0502661D0 (en) * 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
EP1869171B2 (en) * 2005-04-11 2015-10-14 Crucell Holland B.V. Virus purification using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
ES2532015T3 (es) 2008-11-03 2015-03-23 Crucell Holland B.V. Método para la producción de vectores adenovíricos
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
WO2012038367A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
CN103269716B (zh) * 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CN104379733B (zh) 2012-03-12 2016-01-20 克鲁塞尔荷兰公司 具改变末端的重组腺病毒群
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
BR112014023196B1 (pt) 2012-03-22 2021-09-08 Janssen Vaccines & Prevention B.V. Vacinas contra o vírus sincicial respiratório (rsv), seu método de produção, e ácido nucleico recombinante isolado
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
SG11201500171YA (en) 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
HUE041659T2 (hu) 2013-04-25 2019-05-28 Janssen Vaccines & Prevention Bv Stabilizált oldható pre-fúziós RSV F polipeptidek
MX362792B (es) 2013-06-17 2019-02-13 Janssen Vaccines & Prevention Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados.
CN106103471B (zh) 2014-01-09 2020-01-07 特兰斯吉恩股份有限公司 异源寡聚分枝杆菌抗原的融合
US9721484B2 (en) 2014-06-23 2017-08-01 Humanetics Innovative Solutions, Inc. Shoulder kit assembly for crash test dummy
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
US10008130B2 (en) 2014-09-17 2018-06-26 Humanetics Innovative Solutions, Inc. Omni-directional shoulder assembly for crash test dummy
US20180028626A1 (en) 2015-02-13 2018-02-01 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN107466324B (zh) 2015-04-14 2022-01-14 扬森疫苗与预防公司 具有双向启动子的表达两种转基因的重组腺病毒
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
SG11201807913XA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
MX388872B (es) 2016-05-12 2025-03-20 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
BR112018074483A2 (pt) 2016-05-30 2019-03-19 Janssen Vaccines & Prevention B.V. proteínas f do rsv pré-fusão estabilizadas
KR102307065B1 (ko) 2016-06-20 2021-09-30 얀센 백신스 앤드 프리벤션 비.브이. 강력하고 균형 잡힌 양방향성 프로모터
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2018122088A1 (en) 2016-12-28 2018-07-05 Transgene Sa Oncolytic viruses and therapeutic molecules
KR102111244B1 (ko) 2017-02-09 2020-05-15 얀센 백신스 앤드 프리벤션 비.브이. 이종 유전자의 발현을 위한 강력한 짧은 프로모터
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
KR20200053518A (ko) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 면역의 안전한 유도를 위한 방법
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
US12263197B2 (en) 2018-10-30 2025-04-01 The University Of Tokyo Oncolytic virus for cancer therapy
CR20210306A (es) 2018-11-13 2021-07-22 Janssen Vaccines & Prevention Bv Proteínas f de prefusión del vrs estabilizadas
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
AU2021237818A1 (en) 2020-03-19 2022-09-29 Ferring Ventures Ltd. Temperature-responsive virus storage system
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
KR20230152035A (ko) 2021-02-01 2023-11-02 에쓰티 피에이치아이 테라퓨틱스 컴퍼니 리미티드 표적 단백질 분해 시스템 및 이의 응용
MX2023009738A (es) 2021-02-19 2023-08-30 Janssen Vaccines & Prevention Bv Antigenos de rsv fb prefusion estabilizados.
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
JP2025523573A (ja) 2022-07-01 2025-07-23 トランジェーヌ サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
AU7971194A (en) * 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
FR2711523B1 (fr) * 1993-10-26 1996-02-16 Transgene Sa Procédé de préparation d'un aérosol viral.
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations

Also Published As

Publication number Publication date
US6451256B1 (en) 2002-09-17
FR2751343A1 (fr) 1998-01-23
ATE231549T1 (de) 2003-02-15
EP0853660B1 (fr) 2003-01-22
JP3681401B2 (ja) 2005-08-10
US20030082206A1 (en) 2003-05-01
DE69718612T2 (de) 2003-11-06
FR2751343B1 (fr) 1998-12-18
JP2000500026A (ja) 2000-01-11
AU3698697A (en) 1998-02-09
EP0853660A1 (fr) 1998-07-22
DK0853660T3 (da) 2003-05-05
AU711409B2 (en) 1999-10-14
CA2232604A1 (fr) 1998-01-22
WO1998002522A1 (fr) 1998-01-22
DE69718612D1 (de) 2003-02-27
ES2187798T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
CA2232604C (fr) Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
EP0698108B1 (fr) Vecteurs adenoviraux d'origine animale et utilisation en therapie genique
US7033750B2 (en) Recombinant P53 adenovirus methods and compositions
ES2290613T3 (es) Composiciones que comprenden virus y metodos para concentrar preparaciones de virus.
EP2485766B1 (fr) Excipient stabilisant pour vaccins a virus entiers inactifs
CN116546976A (zh) 脂质纳米颗粒的改进工艺和配制
JPH09504429A (ja) 組換えウイルスの保存方法
FR2763958A1 (fr) Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
US20150313926A1 (en) Syn3 compositions and methods
US20030153065A1 (en) Composition and method for maintaining non-enveloped viral vectors
EP1194529A1 (fr) Composition destinee a la conservation d'adenovirus recombinants infectieux
CN114903922B (zh) 包含腺病毒的医药配制品及其保存方法
CN115337408A (zh) 腺相关病毒制剂
CA2370404A1 (fr) Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
CA2173338C (fr) Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodegeneratives
CA2272637A1 (fr) Composition transfectante utile en therapie genique associant a un virus recombinant incorporant un acide nucleique exogene, un agent de transfection non viral et non plasmidique
FR2791999A1 (fr) Composition destinee a la conservation d'adenovirus recombinants infectieux

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170717